The use of prostate-specific antigen density (PSAd) in combination with multiparametric magnetic resonance imaging (mpMRI) of the prostate can improve accuracy of the prostate cancer (PCa) diagnostic pathway.
However, it is not clear whether the performance characteristics of PSAd vary according to the index lesion location (ILL) on mpMRI.
